Position
Fidelity in Travere Therapeutics, Inc.
Back to the book · All holders of TVTX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $272.7M$15.56 → $47.42
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 39.9M | $410.5M | — | — | — | 0.0% |
| Q1 2026 | 21.8M | $339.5M | $15.56 | $114.9M | −$185.9M | 0.0% |
| Q2 2026 | 8.56M | $405.9M | $47.42 | $272.7M | −$206.4M | 0.0% |